Product Introduction
Bioactivity


英文名: Birinapant

描述: Birinapant (TL32711) 是一种二价 Smac 模拟物，是 XIAP 和 cIAP1的强效拮抗剂，Kd 值分别为 45 nM 和小于 1 nM。它靶向与 TRAF2 相关的 cIAP，并消除 TNF 诱导的 NF-κB 活化。

细胞实验: Cells are allowed to attach for 24 hours and subsequently incubated with Birinapant and/or TNF-α for 24 or 72 hours. Then MTS assay is conducted(Only for Reference)

激酶实验: Fluorescence polarization assay: The binding affinities of compounds to XIAP and cIAP1 are determined using a fluorogenic substrate and are reported as Kd values. Initially, the dissociation constant (Kd) for the fluorescently labeled modified Smac peptide (AbuRPF-K(5-Fam)-NH2; FP pep-tide) is determined using a fixed concentration of peptide (5 nM) and titrating varying concentrations of protein (0.075–5 μM in half log dilutions). The dose–response curves are produced by a nonlinear least squares fit to a single-site binding model using GraphPad Prism, with 5 nM of FP peptide and 50 nM of XIAP used in the assay. Various concentrations of Smac mimetics (100–0.001 μM in half log dilutions) are added to FP peptide:protein binary complex for 15 min at room temperature in 100μL of 0.1 M potassium phosphate buffer, pH 7.5, containing 100 mg/mL bovine c -globulin. Following incubation, the polarization values are measured on a multi-label plate reader using a 485 nm excitation filter and a 520 nm emission filter.

体外活性: Birinapant binds with XIAP and cIAP1 with Kd of 45 and <1 nM, respectively. Birinapant induces cell death as a single agent in TRAIL-insensitive SUM190 (ErbB2-overexpressing) cells (IC50, ~300 nM), and significantly increases potency of TRAIL-induced apoptosis in TRAIL-sensitive SUM149 (triple-negative, EGFR-activated) cells. Birinapant causes rapid cIAP1 degradation, caspase activation, PARP cleavage, and NF-κB activation. [1] Birinapant in combination with TNF-α exhibits a strong antimelanoma effect in vitro. Birinapant in combination with TNF-α(1 ng/mL) inhibits the growth of human melanoma cell lines WTH202, WM793B, WM1366 and WM164 with IC50s of 1.8, 2.5, 7.9 and 9 nM, respectively, while neither compound is effective individually. Birinapant singly treatment induces inhibition on proliferation of WM9 cells with IC50 of 2.4 nM. Birinapant significantly inhibits the target protein cIAP1 and cIAP2 in these cell lines.[2]

体内活性: Birinapant (30 mg/kg) treatment significantly induces abrogation of tumor growth in melanoma xenotransplantation models 451Lu with. [2]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : 51 mg/mL (63.2 mM)
DMSO : 93 mg/mL (115.3 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)


关键字: Apoptosis | inhibit | Inhibitor | IAP | TL-32711 | Birinapant | HIV | Human immunodeficiency virus | TL 32711

相关产品: KT5823 | Ro 41-5253 | Butein | Alda-1 | Sandacanol | Cardanol (C15:1) | (Z)-Guggulsterone | ICCB280 | DMU-212 | Fosbretabulin Disodium

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | Hematonosis Compound Library | Cuproptosis Compound Library | Anti-Viral Compound Library | NO PAINS Compound Library | Anti-Infection Compound Library